Skip to main content
. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197

Figure 1.

Figure 1

Cumulative incidence of all‐cause mortality in rivaroxaban vs warfarin arms in the intention‐to‐treat population.